Bis(7)-Tacrine is primarily studied for its potential applications in the treatment of neurodegenerative diseases, particularly Alzheimer's disease. It functions as a dual-binding site acetylcholinesterase inhibitor, which means it can enhance cholinergic transmission by preventing the breakdown of acetylcholine in the brain. This action helps improve cognitive functions such as memory and learning, which are often impaired in Alzheimer's patients. Additionally, it has shown promise in reducing amyloid-beta aggregation, a key pathological feature of Alzheimer's, making it a compound of interest for further research in neuroprotective therapies. Its unique structure allows it to interact with multiple targets, potentially offering broader therapeutic benefits compared to single-target inhibitors.